115 related articles for article (PubMed ID: 21050768)
1. Design and synthesis of an androgen receptor pure antagonist (CH5137291) for the treatment of castration-resistant prostate cancer.
Yoshino H; Sato H; Shiraishi T; Tachibana K; Emura T; Honma A; Ishikura N; Tsunenari T; Watanabe M; Nishimoto A; Nakamura R; Nakagawa T; Ohta M; Takata N; Furumoto K; Kimura K; Kawata H
Bioorg Med Chem; 2010 Dec; 18(23):8150-7. PubMed ID: 21050768
[TBL] [Abstract][Full Text] [Related]
2. Biological properties of androgen receptor pure antagonist for treatment of castration-resistant prostate cancer: optimization from lead compound to CH5137291.
Kawata H; Arai S; Nakagawa T; Ishikura N; Nishimoto A; Yoshino H; Shiraishi T; Tachibana K; Nakamura R; Sato H
Prostate; 2011 Sep; 71(12):1344-56. PubMed ID: 21308717
[TBL] [Abstract][Full Text] [Related]
3. Structure-activity relationships of bioisosteric replacement of the carboxylic acid in novel androgen receptor pure antagonists.
Yoshino H; Sato H; Tachibana K; Shiraishi T; Nakamura M; Ohta M; Ishikura N; Nagamuta M; Onuma E; Nakagawa T; Arai S; Ahn KH; Jung KY; Kawata H
Bioorg Med Chem; 2010 May; 18(9):3159-68. PubMed ID: 20381361
[TBL] [Abstract][Full Text] [Related]
4. CH5137291, an androgen receptor nuclear translocation-inhibiting compound, inhibits the growth of castration-resistant prostate cancer cells.
Ishikura N; Kawata H; Nishimoto A; Nakamura R; Tsunenari T; Watanabe M; Tachibana K; Shiraishi T; Yoshino H; Honma A; Emura T; Ohta M; Nakagawa T; Houjo T; Corey E; Vessella RL; Aoki Y; Sato H
Int J Oncol; 2015 Apr; 46(4):1560-72. PubMed ID: 25634071
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists.
Yamamoto S; Matsunaga N; Hitaka T; Yamada M; Hara T; Miyazaki J; Santou T; Kusaka M; Yamaoka M; Kanzaki N; Furuya S; Tasaka A; Hamamura K; Ito M
Bioorg Med Chem; 2012 Jan; 20(1):422-34. PubMed ID: 22094279
[TBL] [Abstract][Full Text] [Related]
6. Identification of EP4 as a potential target for the treatment of castration-resistant prostate cancer using a novel xenograft model.
Terada N; Shimizu Y; Kamba T; Inoue T; Maeno A; Kobayashi T; Nakamura E; Kamoto T; Kanaji T; Maruyama T; Mikami Y; Toda Y; Matsuoka T; Okuno Y; Tsujimoto G; Narumiya S; Ogawa O
Cancer Res; 2010 Feb; 70(4):1606-15. PubMed ID: 20145136
[TBL] [Abstract][Full Text] [Related]
7. Development of a benzopyran-containing androgen receptor antagonist to treat antiandrogen-resistant prostate cancer.
Oh S; Nam HJ; Park J; Beak SH; Park SB
ChemMedChem; 2010 Apr; 5(4):529-33. PubMed ID: 20135667
[No Abstract] [Full Text] [Related]
8. Design, synthesis, and biological evaluation of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives as novel androgen receptor antagonists.
Yamamoto S; Kobayashi H; Kaku T; Aikawa K; Hara T; Yamaoka M; Kanzaki N; Hasuoka A; Baba A; Ito M
Bioorg Med Chem; 2013 Jan; 21(1):70-83. PubMed ID: 23199477
[TBL] [Abstract][Full Text] [Related]
9. Structure-activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer (CRPC).
Jung ME; Ouk S; Yoo D; Sawyers CL; Chen C; Tran C; Wongvipat J
J Med Chem; 2010 Apr; 53(7):2779-96. PubMed ID: 20218717
[TBL] [Abstract][Full Text] [Related]
10. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.
Hara T; Miyazaki J; Araki H; Yamaoka M; Kanzaki N; Kusaka M; Miyamoto M
Cancer Res; 2003 Jan; 63(1):149-53. PubMed ID: 12517791
[TBL] [Abstract][Full Text] [Related]
11. Design and synthesis of androgen receptor full antagonists bearing a p-carborane cage: promising ligands for anti-androgen withdrawal syndrome.
Goto T; Ohta K; Fujii S; Ohta S; Endo Y
J Med Chem; 2010 Jul; 53(13):4917-26. PubMed ID: 20521823
[TBL] [Abstract][Full Text] [Related]
12. Arachidonic acid activation of intratumoral steroid synthesis during prostate cancer progression to castration resistance.
Locke JA; Guns ES; Lehman ML; Ettinger S; Zoubeidi A; Lubik A; Margiotti K; Fazli L; Adomat H; Wasan KM; Gleave ME; Nelson CC
Prostate; 2010 Feb; 70(3):239-51. PubMed ID: 19790237
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists.
Yamamoto S; Tomita N; Suzuki Y; Suzaki T; Kaku T; Hara T; Yamaoka M; Kanzaki N; Hasuoka A; Baba A; Ito M
Bioorg Med Chem; 2012 Apr; 20(7):2338-52. PubMed ID: 22391033
[TBL] [Abstract][Full Text] [Related]
14. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
Culig Z; Hoffmann J; Erdel M; Eder IE; Hobisch A; Hittmair A; Bartsch G; Utermann G; Schneider MR; Parczyk K; Klocker H
Br J Cancer; 1999 Sep; 81(2):242-51. PubMed ID: 10496349
[TBL] [Abstract][Full Text] [Related]
15. Steroid hormone receptors as targets for the therapy of breast and prostate cancer--recent advances, mechanisms of resistance, and new approaches.
Hoffmann J; Sommer A
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):191-200. PubMed ID: 15860262
[TBL] [Abstract][Full Text] [Related]
16. Antiandrogenic, maspin induction, and antiprostate cancer activities of tanshinone IIA and its novel derivatives with modification in ring A.
Liu W; Zhou J; Geng G; Shi Q; Sauriol F; Wu JH
J Med Chem; 2012 Jan; 55(2):971-5. PubMed ID: 22175694
[TBL] [Abstract][Full Text] [Related]
17. In vivo knockdown of the androgen receptor results in growth inhibition and regression of well-established, castration-resistant prostate tumors.
Snoek R; Cheng H; Margiotti K; Wafa LA; Wong CA; Wong EC; Fazli L; Nelson CC; Gleave ME; Rennie PS
Clin Cancer Res; 2009 Jan; 15(1):39-47. PubMed ID: 19118031
[TBL] [Abstract][Full Text] [Related]
18. Unexpected binding orientation of bulky-B-ring anti-androgens and implications for future drug targets.
Duke CB; Jones A; Bohl CE; Dalton JT; Miller DD
J Med Chem; 2011 Jun; 54(11):3973-6. PubMed ID: 21506597
[TBL] [Abstract][Full Text] [Related]
19. (+)-(2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3- yl]piperazine-1-carboxamide (YM580) as an orally potent and peripherally selective nonsteroidal androgen receptor antagonist.
Kinoyama I; Taniguchi N; Toyoshima A; Nozawa E; Kamikubo T; Imamura M; Matsuhisa A; Samizu K; Kawanimani E; Niimi T; Hamada N; Koutoku H; Furutani T; Kudoh M; Okada M; Ohta M; Tsukamoto S
J Med Chem; 2006 Jan; 49(2):716-26. PubMed ID: 16420057
[TBL] [Abstract][Full Text] [Related]
20. Hormonal therapy of prostate cancer.
Labrie F
Prog Brain Res; 2010; 182():321-41. PubMed ID: 20541672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
